サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1722482

肝疾患治療市場レポート：治療タイプ、疾患タイプ、エンドユーザー、地域別、2025年～2033年

Liver Disease Treatment Market Report by Treatment Type, Disease Type (Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liver Disease, Cancer, Genetic Disorders, and Others), End User, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 150 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.36円
肝疾患治療市場レポート：治療タイプ、疾患タイプ、エンドユーザー、地域別、2025年～2033年
出版日: 2025年05月01日
発行: IMARC
ページ情報: 英文 150 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の肝疾患治療の市場規模は2024年に251億米ドルに達しました。今後、IMARC Groupは、2033年には404億米ドルに達し、2025～2033年の成長率（CAGR）は5.44％になると予測しています。肝疾患を含むいくつかの慢性疾患にかかりやすい高齢者人口が世界的に増加していることが、市場を刺激しています。

肝臓は、ビタミンや栄養素の貯蔵、血液中の有害物質の除去、体内の化学物質の適切なバランスの維持など、重要な機能を果たす人体の重要な臓器です。がん、肝炎、自己免疫疾患、遺伝的疾患は、一般的な肝疾患の一部です。これらの病気は一般的に、感染症、遺伝、肥満、糖尿病、免疫系の異常によって引き起こされます。肝疾患の治療法として広く用いられているものには、ワクチン、化学療法、抗ウイルス薬、免疫グロブリン、副腎皮質ステロイド、免疫抑制剤などがあります。肝疾患治療は、コレステロールやホルモンの排泄を助け、胆汁の生産と酵素の活性化を増加させます。

肝疾患治療の市場動向：

肝疾患を含む様々な慢性疾患に罹患しやすい老年人口が世界中で増加していることは、市場の成長を促進する主要因の一つです。食事パターンの変化と座りがちなライフスタイルが市場の成長を後押ししています。さらに、高コレステロール、肥満、高血圧（高血圧）、糖尿病による脂肪肝疾患の有病率の増加が、市場の成長を後押ししています。さらに、バイオ人工肝臓の開発など、さまざまな技術の進歩が市場成長に弾みをつけています。これは再生肝細胞を利用して肝機能を代替するもので、急性肝不全患者に広く使用されています。これに伴い、安全かつ効果的で、B型肝炎ウイルスの抑制を助け、肝硬変や肝細胞がんの開発リスクを軽減する抗ウイルス薬の急速な普及が、市場開拓にプラスの影響を与えています。これとは別に、研究開発（R&D）活動の増加、ヘルスケア産業の著しい成長、公衆衛生を促進するためのさまざまな政府イニシアチブの実施が、市場に明るい見通しを生み出しています。

本レポートで扱う主な質問

  • 2024年の世界の肝疾患治療市場規模は？
  • 2025年～2033年の世界の肝疾患治療市場の予想成長率は？
  • 肝疾患治療の世界市場を牽引する主要因は？
  • 肝疾患治療の世界市場におけるCOVID-19の影響は？
  • 肝疾患治療の世界市場における治療タイプ別の区分は？
  • 肝疾患治療の世界市場における疾患タイプ別の区分は？
  • 肝疾患治療の世界市場をエンドユーザー別に区分すると？
  • 肝疾患治療の世界市場における主要地域は？
  • 世界の肝疾患治療市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の肝疾患治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：治療タイプ別

  • 抗ウイルス薬
  • 免疫抑制剤
  • ワクチン
  • 免疫グロブリン
  • コルチコステロイド
  • 標的療法
  • 化学療法

第7章 市場内訳：疾患タイプ別

  • 肝炎
  • 自己免疫疾患
  • 非アルコール性脂肪性肝疾患（NAFLD）
  • がん
  • 遺伝性疾患
  • その他

第8章 市場内訳：エンドユーザー別

  • 病院
  • 外来手術センター
  • その他

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場内訳：国別

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Emergent BioSolutions Inc.
    • F. Hoffmann-La Roche AG
    • Gilead Sciences Inc.
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
    • Viatris Inc.
図表

List of Figures

  • Figure 1: Global: Liver Disease Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Liver Disease Treatment Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Liver Disease Treatment Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Liver Disease Treatment Market: Breakup by Treatment Type (in %), 2024
  • Figure 5: Global: Liver Disease Treatment Market: Breakup by Disease Type (in %), 2024
  • Figure 6: Global: Liver Disease Treatment Market: Breakup by End User (in %), 2024
  • Figure 7: Global: Liver Disease Treatment Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Liver Disease Treatment (Antiviral Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Liver Disease Treatment (Antiviral Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Liver Disease Treatment (Immunosuppressants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Liver Disease Treatment (Immunosuppressants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Liver Disease Treatment (Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Liver Disease Treatment (Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Liver Disease Treatment (Immunoglobulins) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Liver Disease Treatment (Immunoglobulins) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Liver Disease Treatment (Corticosteroids) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Liver Disease Treatment (Corticosteroids) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Liver Disease Treatment (Targeted Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Liver Disease Treatment (Targeted Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Liver Disease Treatment (Chemotherapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Liver Disease Treatment (Chemotherapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Liver Disease Treatment (Hepatitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Liver Disease Treatment (Hepatitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Liver Disease Treatment (Autoimmune Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Liver Disease Treatment (Autoimmune Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Liver Disease Treatment (Non-alcoholic Fatty Liver Disease (NAFLD)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Liver Disease Treatment (Non-alcoholic Fatty Liver Disease (NAFLD)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Liver Disease Treatment (Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Liver Disease Treatment (Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Liver Disease Treatment (Genetic Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Liver Disease Treatment (Genetic Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Liver Disease Treatment (Other Disease Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Liver Disease Treatment (Other Disease Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Liver Disease Treatment (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Liver Disease Treatment (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Liver Disease Treatment (Ambulatory Surgical Centers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Liver Disease Treatment (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: Liver Disease Treatment (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Global: Liver Disease Treatment (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: North America: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: North America: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: United States: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: United States: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Canada: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Canada: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Asia-Pacific: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Asia-Pacific: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: China: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: China: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Japan: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Japan: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: India: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: India: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: South Korea: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: South Korea: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Australia: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Australia: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Indonesia: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Indonesia: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Others: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Others: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Europe: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Europe: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Germany: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Germany: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: France: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: France: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: United Kingdom: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: United Kingdom: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Italy: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Italy: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Spain: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Spain: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Russia: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Russia: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Others: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Others: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Latin America: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Latin America: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Brazil: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Brazil: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Mexico: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Mexico: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Others: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: Others: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 86: Middle East and Africa: Liver Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 87: Middle East and Africa: Liver Disease Treatment Market: Breakup by Country (in %), 2024
  • Figure 88: Middle East and Africa: Liver Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Global: Liver Disease Treatment Industry: SWOT Analysis
  • Figure 90: Global: Liver Disease Treatment Industry: Value Chain Analysis
  • Figure 91: Global: Liver Disease Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Liver Disease Treatment Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Liver Disease Treatment Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
  • Table 3: Global: Liver Disease Treatment Market Forecast: Breakup by Disease Type (in Million USD), 2025-2033
  • Table 4: Global: Liver Disease Treatment Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Liver Disease Treatment Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Liver Disease Treatment Market: Competitive Structure
  • Table 7: Global: Liver Disease Treatment Market: Key Players
目次
Product Code: SR112025A5023

The global liver disease treatment market size reached USD 25.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 40.4 Billion by 2033, exhibiting a growth rate (CAGR) of 5.44% during 2025-2033. The growing elderly population worldwide, which is prone to several chronic illnesses, including liver disease, is stimulating the market.

The liver is a vital organ of the human body that performs significant functions, such as storing vitamins and nutrients, removing harmful substances from the blood, and maintaining an adequate balance of chemicals in the body. Cancer, hepatitis, autoimmune diseases, and genetic disorders are some common liver diseases. These diseases are commonly caused by infections, genetics, obesity, diabetes, and immune system abnormalities. Some of the widely used therapeutic techniques for liver diseases include vaccines, chemotherapy, antiviral drugs, immunoglobulins, corticosteroids, and immunosuppressants. Liver disease treatment aids in the excretion of cholesterol and hormones, increases bile production and enzyme activation.

Liver Disease Treatment Market Trends:

The rising geriatric population, which is suspetible to various chronic ailments, including liver disease, across the globe is one of the prime factors driving the growth of the market. The changing dietary patterns and sedentary lifestyles are boosting the market growth. Additionally, the increasing prevalence of fatty liver disease due to high cholesterol, obesity, hypertension (high blood pressure), and diabetes is favoring the market growth. Moreover, various technological advancements, such as the development of the bioartificial liver, are providing an impetus to the market growth. It utilizes regenerated liver cells to replace liver functions and is widely used for acute liver failure patients. In line with this, the rapid adoption of antiviral drugs as they are safe and effective, assist in suppressing the hepatitis B virus, and help in reducing the risk of developing cirrhosis and hepatocellular carcinoma, is positively impacting the market growth. Apart from this, increasing research and development (R&D) activities, significant growth in the healthcare industry, and the implementation of various government initiatives to promote public health are creating a positive outlook for the market.

Key Market Segmentation:

Breakup by Treatment Type:

  • Antiviral Drugs
  • Immunosuppressants
  • Vaccines
  • Immunoglobulins
  • Corticosteroids
  • Targeted Therapy
  • Chemotherapy

Breakup by Disease Type:

  • Hepatitis
  • Autoimmune Diseases
  • Non-alcoholic Fatty Liver Disease (NAFLD)
  • Cancer
  • Genetic Disorders
  • Others

Breakup by End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Viatris Inc.

Key Questions Answered in This Report

  • 1.What was the size of the global liver disease treatment market in 2024?
  • 2.What is the expected growth rate of the global liver disease treatment market during 2025-2033?
  • 3.What are the key factors driving the global liver disease treatment market?
  • 4.What has been the impact of COVID-19 on the global liver disease treatment market?
  • 5.What is the breakup of the global liver disease treatment market based on the treatment type?
  • 6.What is the breakup of the global liver disease treatment market based on the disease type?
  • 7.What is the breakup of the global liver disease treatment market based on the end user?
  • 8.What are the key regions in the global liver disease treatment market?
  • 9.Who are the key players/companies in the global liver disease treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Liver Disease Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Antiviral Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Immunosuppressants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Vaccines
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Immunoglobulins
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Corticosteroids
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Targeted Therapy
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Chemotherapy
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Hepatitis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Autoimmune Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Non-alcoholic Fatty Liver Disease (NAFLD)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cancer
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Genetic Disorders
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ambulatory Surgical Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AbbVie Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Astellas Pharma Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Emergent BioSolutions Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 F. Hoffmann-La Roche AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Gilead Sciences Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 GlaxoSmithKline plc
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck & Co. Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Novartis AG
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Pfizer Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Sanofi S.A.
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis
    • 14.3.14 Takeda Pharmaceutical Company Limited
      • 14.3.14.1 Company Overview
      • 14.3.14.2 Product Portfolio
      • 14.3.14.3 Financials
      • 14.3.14.4 SWOT Analysis
    • 14.3.15 Viatris Inc.
      • 14.3.15.1 Company Overview
      • 14.3.15.2 Product Portfolio
      • 14.3.15.3 Financials